Epigallocatechin‑3‑gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase‑2

Wang,Feng; Chang,Zhiwei; Fan,Qingxia; Wang,Liuxing

doi:10.3892/mmr.2014.1909

Epigallocatechin‑3‑gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase‑2

Authors:
- Feng Wang
- Zhiwei Chang
- Qingxia Fan
- Liuxing Wang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 22, 2014 https://doi.org/10.3892/mmr.2014.1909
Pages: 1085-1089

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epigallocatechin‑3‑gallate (EGCG), a major catechin in green tea, has recently been reported to exhibit anticancer effects on a number of types of cancer cells in vitro; however, the molecular mechanisms of this anticancer effect remain poorly understood. In the current study, the effects of EGCG on the proliferation and migration of the OVCAR‑3 human ovarian carcinoma cell line were investigated. Cells were treated with EGCG and their proliferation rates were determined by an MTT assay. In addition, cell migration was detected by transwell assay. The activity of mitogen‑activated protein kinases (MAPKs) and the expression of matrix metalloproteinase‑2/9 (MMP‑2/9) were examined by western blotting. The results showed that EGCG significantly inhibited (P<0.05) the proliferation of OVCAR‑3 cells in a time‑ and concentration‑dependent manner. EGCG (100 µM) time‑dependently increased (P<0.05) the activity of p38, but not extracellular signal‑regulated kinases 1/2. SB203580, a specific p38 MAPK inhibitor, completely diminished EGCG‑induced phosphorylation of p38 and partially blocked EGCG‑inhibited OVCAR‑3 cell proliferation. Furthermore, EGCG (0‑100 µM) dose‑dependently inhibited (P<0.05) OVCAR‑3 cell migration. The protein expression levels of MPP‑2, but not MMP‑9, were dose‑dependently decreased following treatment with EGCG (0‑100 µM) for 48 h. These data indicated that EGCG inhibited OVCAR‑3 cell proliferation and migration, potentially mediated via the activation of p38 MAPK and downregulation of the protein expression of MMP2. Thus, the therapeutic potential of EGCG for ovarian cancer requires further investigation.

View Figures

View References

1	Katiyar SK and Elmets CA: Green tea polyphenolic antioxidants and skin photoprotection (Review). Int J Oncol. 18:1307–1313. 2001.PubMed/NCBI
2	Singh BN, Shankar S and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 82:1807–1821. 2011. View Article : Google Scholar : PubMed/NCBI
3	Mukhtar H and Ahmad N: Green tea in chemoprevention of cancer. Toxicol Sci. 52(2 Suppl): S111–S117. 1999. View Article : Google Scholar
4	Hsu YC and Liou YM: The anti-cancer effects of (-)-epigallocatechin-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. J Cell Physiol. 226:2721–2730. 2011. View Article : Google Scholar : PubMed/NCBI
5	Shankar S, Ganapathy S, Hingorani SR and Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci. 13:440–452. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sukhthankar M, Alberti S and Baek SJ: (-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells. Anticancer Res. 30:2497–2503. 2010.PubMed/NCBI
7	Onoda C, Kuribayashi K, Nirasawa S, Tsuji N, Tanaka M, Kobayashi D and Watanabe N: (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression. Int J Oncol. 38:1403–1408. 2011.PubMed/NCBI
8	Cho KR and Shih IeM: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar
9	Urban N and Drescher C: Potential and limitations in early diagnosis of ovarian cancer. Adv Exp Med Biol. 622:3–14. 2008. View Article : Google Scholar : PubMed/NCBI
10	Mizutani K, Ito H, Iwamoto I, et al: Essential roles of ERK-mediated phosphorylation of vinexin in cell spreading, migration and anchorage-independent growth. Oncogene. 26:7122–7131. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ray RM, Vaidya RJ and Johnson LR: MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil Cytoskeleton. 64:143–156. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kang YH, Yang IJ and Shin HM: Herbal formula HMC05 prevents human aortic smooth muscle cell migration and proliferation by inhibiting the ERK1/2 MAPK signaling cascade. J Nat Med. 66:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gayer CP, Craig DH, Flanigan TL, Reed TD, Cress DE and Basson MD: ERK regulates strain-induced migration and proliferation from different subcellular locations. J Cell Biochem. 109:711–725. 2010.PubMed/NCBI
15	Tangkijvanich P, Santiskulvong C, Melton AC, Rozengurt E and Yee HF Jr: p38 MAP kinase mediates platelet-derived growth factor-stimulated migration of hepatic myofibroblasts. J Cell Physiol. 191:351–361. 2002. View Article : Google Scholar : PubMed/NCBI
16	Li T, Feng Z, Jia S, Wang W, Du Z, Chen N and Chen Z: Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast Cancer Res Treat. 131:891–898. 2012.PubMed/NCBI
17	Xue A, Xue M, Jackson C and Smith RC: Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling. Int J Biochem Cell Biol. 41:1731–1738. 2009. View Article : Google Scholar : PubMed/NCBI
18	Choi BD, Jeong SJ, Wang G, Park JJ, Lim DS, Kim BH, Cho YI, Kim CS and Jeong MJ: Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells. Int J Mol Med. 28:527–534. 2011.PubMed/NCBI
19	Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 11:1696–1701. 2006. View Article : Google Scholar : PubMed/NCBI
20	Hilger RA, Scheulen ME and Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 25:511–518. 2002. View Article : Google Scholar : PubMed/NCBI
21	Geest CR and Coffer PJ: MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol. 86:237–250. 2009. View Article : Google Scholar : PubMed/NCBI
22	Brooks SA, Lomax-Browne HJ, Carter TM, et al: Molecular interactions in cancer cell metastasis. Acta Histochem. 112:3–25. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010. View Article : Google Scholar : PubMed/NCBI
24	Roy R, Yang J and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 27:5287–5297. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hwang ES and Park KK: Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci Biotechnol Biochem. 74:961–967. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sun LC, Luo J, Mackey LV, Fuselier JA and Coy DH: A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett. 246:157–166. 2007. View Article : Google Scholar : PubMed/NCBI
27	Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W and Lengyel E: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 7:2396–2404. 2001.PubMed/NCBI
28	Deng YT and Lin JK: EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem. 59:13318–13327. 2011. View Article : Google Scholar : PubMed/NCBI
29	Sen T, Moulik S, Dutta A, Choudhury PR, Banerji A, Das S, Roy M and Chatterjee A: Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 84:194–204. 2009. View Article : Google Scholar : PubMed/NCBI